Long‐term in‐vitro treatment of human growth hormone (GH)‐secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels

OBJECTIVE We studied the effects of long‐term in‐vitro exposure of human GH secreting pituitary adenoma cells to octreotide on GH release, intracellular GH concentrations and GH messengerbonuclelc acid (mRNA) levels.

[1]  E. Hooghe-Peters,et al.  The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH‐secreting pituitary adenomas , 1991, Clinical endocrinology.

[2]  S. Lamberts,et al.  Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. , 1990, The Journal of clinical endocrinology and metabolism.

[3]  E. Wilson,et al.  Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro. , 1989, The Journal of clinical endocrinology and metabolism.

[4]  S. Lamberts,et al.  GLYCOPROTEIN HORMONE ALPHA‐SUBUNIT AND PROLACTIN RELEASE BY CULTURED PITUITARY ADENOMA CELLS FROM ACROMEGALIC PATIENTS: CORRELATION WITH GH RELEASE , 1989, Clinical endocrinology.

[5]  S. Melmed,et al.  Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide. , 1989, Archives of internal medicine.

[6]  S. Lamberts,et al.  Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. , 1989, The Journal of clinical endocrinology and metabolism.

[7]  S. Melmed,et al.  Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin. , 1989, Endocrinology.

[8]  S. Lamberts,et al.  Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone. , 1989, The Journal of clinical endocrinology and metabolism.

[9]  S. Lamberts.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. , 1988, Endocrine reviews.

[10]  S. Gebarski,et al.  Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. , 1988, The Journal of clinical endocrinology and metabolism.

[11]  L. Vanhaelst,et al.  Prolactin cell subpopulations separated on discontinuous Percoll gradient: an immunocytochemical, biochemical, and physiological characterization. , 1988, Endocrinology.

[12]  S. Lightman,et al.  Quantitative in-situ hybridization histochemistry studies on growth hormone (GH) gene expression in acromegalic somatotrophs: effects of somatostatin, GH-releasing factor and cortisol. , 1988, Journal of molecular endocrinology.

[13]  S. Lamberts,et al.  SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. , 1987, The Journal of clinical endocrinology and metabolism.

[14]  K. Docherty,et al.  A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro , 1987, Molecular and Cellular Endocrinology.

[15]  F. Takaku,et al.  Secretion of Glycoprotein Hormone α-Subunit by Pituitary Tumors* , 1987 .

[16]  C. Bancroft,et al.  Glucocorticoid stimulation of growth hormone messenger ribonucleic acid levels in GH3 cells is inhibited by calcium but not by somatostatin. , 1987, Endocrinology.

[17]  I. Jackson,et al.  Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. , 1986, The American journal of medicine.

[18]  S. Lamberts,et al.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. , 1985, The New England journal of medicine.

[19]  G. Giannattasio,et al.  Glycoprotein Hormone α-Subunit Response to Growth Hormone(GH)-Releasing Hormone in Patients with Active Acromegaly · Evidence for α-Subunit and GH Coexistence in the Same Tumoral Cell* , 1985 .

[20]  S. Lamberts,et al.  Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration , 1984, Journal of endocrinological investigation.

[21]  G. Giannattasio,et al.  Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. , 1984, The Journal of clinical endocrinology and metabolism.

[22]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[23]  R. Maurer.  Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP , 1981, Nature.

[24]  J. P. O'sullivan,et al.  Effect of bromocriptine, somatostatin, and oestradiol-17 beta on hormone secretion and ultrastructure of human pituitary tumours in vitro. , 1981, Acta endocrinologica.

[25]  R. Maurer.  Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. , 1980, The Journal of biological chemistry.

[26]  P. Rivaille,et al.  [Effect of SRIF (somatostatin) on human somatroptropic adenomas in vitro ultrastructure and growth hormone production (author's transl)(proceedings)]. , 1976, Annales d'endocrinologie.

[27]  W. Miller,et al.  Regulation of growth hormone (GH) secretion by GH-releasing factor, somatostatin, and insulin-like growth factor I in ovine fetal and neonatal pituitary cells in vitro. , 1989, Endocrinology.

[28]  F. Takaku,et al.  Secretion of glycoprotein hormone alpha-subunit by pituitary tumors. , 1987, The Journal of clinical endocrinology and metabolism.

[29]  S. Lamberts.  Antimitotic actions of dopaminergic drugs on human pituitary tumors , 1984 .